Key Drivers
- Strong Liquidity
- Rising Debt
- Negative Cash Flow
AIAI Summary
MIRM's strong LIVMARLI growth and high margins are increasingly offset by rising leverage, negative cash flow, and a valuation dependent on pivotal brelovitug data—making the stock attractive only if pipeline wins can turn growth self-funding before financing risk intensifies.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Rising Debt
- •Negative Cash Flow
MIRM has strong liquidity and margins, but escalating debt, negative equity, large losses, and negative cash flow make its high valuation materially risky.
Price Behavior
Key Price Behavior Insights:
- •Support breakdown
- •Weak momentum
- •Failed rebound
MIRM is bearish over the last month after breaking below $93.90, with $91.80 as critical support and a reclaim of $98.80–$100.90 needed to improve momentum.
Mid-$90s rebound failed sharply on 2026-09-18
Sentiment & News
Key News Insights:
- •Raised Sales Guidance
- •FDA Decision Ahead
- •Institutional Buying
Mirum's raised guidance, institutional buying, and upcoming FDA/pivotal-data catalysts support a constructive outlook despite widening losses and delayed profitability.
Near-term pipeline catalysts could drive volatility and upside if regulatory or clinical results are favorable
Similar Companies in Healthcare
Other companies in the same sector with AI ratings